Kyntra Bio (KYNB) Other Non-Current Assets (2014 - 2026)
Kyntra Bio (KYNB) posted Other Non-Current Assets of $248000.0 for Q1 2026, down 31.3% sequentially from $361000.0 in Q4 2025, and down 98.41% YoY from $15.6 million in Q1 2025.
Kyntra Bio (KYNB) Other Non-Current Assets (2014 - 2026) Analysis & Trends
Kyntra Bio has reported Other Non-Current Assets for 13 years, with the latest figure at $248000.0 in Q1 2026.
- Quarterly Other Non-Current Assets fell 98.41% year-over-year to $248000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $248000.0 (down 98.41% YoY) and the FY2025 annual result came in at $361000.0, down 97.83% from the prior year.
- Other Non-Current Assets slipped to $248000.0 in Q1 2026 per KYNB's latest filing, from $361000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $16.6 million in Q4 2024 and troughed at $248000.0 in Q1 2026.
- A 5-year average of $4.9 million and a median of $2.1 million in 2022 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2024 and 2026: Other Non-Current Assets soared 901.87% in 2024, then slumped 98.41% in 2026.
- Over 5 years, Other Non-Current Assets stood at $2.1 million in 2022, then declined by 19.98% to $1.7 million in 2023, then jumped by 901.87% to $16.6 million in 2024, then plunged by 97.83% to $361000.0 in 2025, then plunged by 31.3% to $248000.0 in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $248000.0, $361000.0, and $14.9 million for Q1 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Kyntra Bio | 30.42 Mn | 30.42 Mn | 1.47 Mn | 241,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 241,000.00 |
| Mar 31, 2026 | 248,000.00 |
| Dec 31, 2025 | 361,000.00 |
| Jun 30, 2025 | 14.89 Mn |
| Mar 31, 2025 | 15.56 Mn |
| Dec 31, 2024 | 16.61 Mn |
| Sep 30, 2024 | 1.66 Mn |
| Jun 30, 2024 | 1.66 Mn |
| Mar 31, 2024 | 1.66 Mn |
| Dec 31, 2023 | 1.66 Mn |
| Sep 30, 2023 | 2.07 Mn |
| Jun 30, 2023 | 4.35 Mn |
| Mar 31, 2023 | 2.07 Mn |
| Dec 31, 2022 | 2.07 Mn |
| Sep 30, 2022 | 2.07 Mn |
| Jun 30, 2022 | 4.50 Mn |
| Mar 31, 2022 | 6.93 Mn |
| Dec 31, 2021 | 6.68 Mn |
| Sep 30, 2021 | 5.11 Mn |
| Jun 30, 2021 | 4.62 Mn |